Unknown

Dataset Information

0

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.


ABSTRACT: BACKGROUND:Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma. METHODS:Patients were randomised (2?:?1) to IMM-101 (10?mg?ml(-l) intradermally)+GEM (1000?mg?m(-2) intravenously; n=75), or GEM alone (n=35). Safety was assessed on frequency and incidence of adverse events (AEs). Overall survival (OS), progression-free survival (PFS) and overall response rate (ORR) were collected. RESULTS:IMM-101 was well tolerated with a similar rate of AE and serious adverse event reporting in both groups after allowance for exposure. Median OS in the intent-to-treat population was 6.7 months for IMM-101+GEM v 5.6 months for GEM; while not significant, the hazard ratio (HR) numerically favoured IMM-101+GEM (HR, 0.68 (95% CI, 0.44-1.04, P=0.074). In a pre-defined metastatic subgroup (84%), OS was significantly improved from 4.4 to 7.0 months in favour of IMM-101+GEM (HR, 0.54, 95% CI 0.33-0.87, P=0.01). CONCLUSIONS:IMM-101 with GEM was as safe and well tolerated as GEM alone, and there was a suggestion of a beneficial effect on survival in patients with metastatic disease. This warrants further evaluation in an adequately powered confirmatory study.

SUBMITTER: Dalgleish AG 

PROVIDER: S-EPMC5046215 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Immune Modulation and Gemcitabine Evaluation-1, a randomised, open-label, phase II, first-line, proof of concept study (NCT01303172), explored safety and tolerability of IMM-101 (heat-killed Mycobacterium obuense; NCTC 13365) with gemcitabine (GEM) in advanced pancreatic ductal adenocarcinoma.<h4>Methods</h4>Patients were randomised (2 : 1) to IMM-101 (10 mg ml(-l) intradermally)+GEM (1000 mg m(-2) intravenously; n=75), or GEM alone (n=35). Safety was assessed on frequency and  ...[more]

Similar Datasets

| S-EPMC6372099 | biostudies-literature
| S-EPMC5556651 | biostudies-literature
| S-EPMC6386028 | biostudies-literature
| S-EPMC4221373 | biostudies-literature
| S-EPMC9361660 | biostudies-literature
| S-EPMC8126718 | biostudies-literature
| S-EPMC7656907 | biostudies-literature
| S-EPMC6651911 | biostudies-literature
| S-EPMC6459252 | biostudies-literature
| S-EPMC5975422 | biostudies-literature